 Cathy Bradley
Concepts (479)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 63 | 2024 | 2118 | 10.900 |
Why?
| | Employment | 37 | 2024 | 139 | 10.040 |
Why?
| | Medicaid | 37 | 2023 | 411 | 8.740 |
Why?
| | Breast Neoplasms | 47 | 2023 | 1872 | 6.240 |
Why?
| | Cancer Survivors | 14 | 2023 | 203 | 4.890 |
Why?
| | Insurance Coverage | 20 | 2023 | 204 | 4.440 |
Why?
| | Insurance, Health | 19 | 2023 | 246 | 4.140 |
Why?
| | Medicare | 34 | 2023 | 666 | 3.810 |
Why?
| | SEER Program | 21 | 2022 | 195 | 3.310 |
Why?
| | Poverty | 13 | 2022 | 448 | 3.240 |
Why?
| | Healthcare Disparities | 14 | 2020 | 485 | 2.920 |
Why?
| | Cost of Illness | 13 | 2022 | 257 | 2.870 |
Why?
| | Colorectal Neoplasms | 15 | 2022 | 617 | 2.760 |
Why?
| | Medically Uninsured | 12 | 2020 | 122 | 2.750 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2020 | 213 | 2.600 |
Why?
| | United States | 89 | 2023 | 12295 | 2.520 |
Why?
| | Early Detection of Cancer | 9 | 2022 | 340 | 2.380 |
Why?
| | Survivors | 16 | 2022 | 404 | 2.280 |
Why?
| | Registries | 31 | 2023 | 1770 | 2.200 |
Why?
| | Health Services Accessibility | 16 | 2023 | 771 | 2.170 |
Why?
| | Health Benefit Plans, Employee | 5 | 2022 | 20 | 2.030 |
Why?
| | Humans | 187 | 2024 | 115587 | 1.890 |
Why?
| | Caregivers | 6 | 2023 | 713 | 1.860 |
Why?
| | Health Care Costs | 13 | 2022 | 384 | 1.810 |
Why?
| | Survivorship | 4 | 2022 | 38 | 1.810 |
Why?
| | Health Care Reform | 4 | 2021 | 92 | 1.620 |
Why?
| | Antineoplastic Agents | 8 | 2020 | 1893 | 1.610 |
Why?
| | Medical Oncology | 5 | 2023 | 230 | 1.550 |
Why?
| | Drug Costs | 3 | 2023 | 91 | 1.520 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 5 | 2020 | 963 | 1.500 |
Why?
| | Colonic Neoplasms | 5 | 2016 | 222 | 1.430 |
Why?
| | Aged | 70 | 2023 | 19251 | 1.420 |
Why?
| | Mental Health | 4 | 2023 | 571 | 1.410 |
Why?
| | Female | 118 | 2023 | 59913 | 1.410 |
Why?
| | Socioeconomic Factors | 20 | 2022 | 1086 | 1.350 |
Why?
| | Research | 6 | 2022 | 396 | 1.320 |
Why?
| | Policy | 4 | 2024 | 140 | 1.310 |
Why?
| | Michigan | 24 | 2015 | 96 | 1.300 |
Why?
| | Middle Aged | 69 | 2023 | 26999 | 1.280 |
Why?
| | Lung Neoplasms | 10 | 2020 | 2207 | 1.270 |
Why?
| | Prostatic Neoplasms | 10 | 2022 | 927 | 1.230 |
Why?
| | Neoplasm Staging | 17 | 2022 | 1178 | 1.220 |
Why?
| | Prescription Drugs | 2 | 2023 | 116 | 1.220 |
Why?
| | Health Status Disparities | 2 | 2023 | 204 | 1.180 |
Why?
| | Income | 7 | 2023 | 170 | 1.170 |
Why?
| | Health Status | 10 | 2013 | 728 | 1.170 |
Why?
| | Medical Record Linkage | 2 | 2021 | 53 | 1.100 |
Why?
| | Aged, 80 and over | 35 | 2020 | 6417 | 1.080 |
Why?
| | Male | 86 | 2022 | 55949 | 1.070 |
Why?
| | Papanicolaou Test | 2 | 2017 | 39 | 1.070 |
Why?
| | Primary Health Care | 6 | 2023 | 1518 | 1.050 |
Why?
| | Motivation | 2 | 2020 | 498 | 1.010 |
Why?
| | Adult | 60 | 2023 | 30718 | 0.990 |
Why?
| | Patient Acceptance of Health Care | 4 | 2018 | 682 | 0.990 |
Why?
| | Efficiency | 6 | 2016 | 84 | 0.990 |
Why?
| | Safety-net Providers | 3 | 2017 | 96 | 0.970 |
Why?
| | Comorbidity | 12 | 2019 | 1473 | 0.900 |
Why?
| | Mass Screening | 10 | 2022 | 1024 | 0.900 |
Why?
| | Eligibility Determination | 5 | 2018 | 60 | 0.900 |
Why?
| | Colonoscopy | 4 | 2019 | 204 | 0.870 |
Why?
| | Health Expenditures | 8 | 2023 | 173 | 0.860 |
Why?
| | Return to Work | 4 | 2022 | 20 | 0.830 |
Why?
| | Absenteeism | 4 | 2013 | 40 | 0.830 |
Why?
| | Quality of Life | 6 | 2023 | 2385 | 0.820 |
Why?
| | Virginia | 7 | 2018 | 51 | 0.800 |
Why?
| | Workplace | 4 | 2021 | 222 | 0.780 |
Why?
| | Health Equity | 1 | 2022 | 56 | 0.770 |
Why?
| | Cancer Care Facilities | 3 | 2023 | 30 | 0.730 |
Why?
| | Medication Adherence | 2 | 2023 | 538 | 0.730 |
Why?
| | Perioperative Care | 1 | 2021 | 126 | 0.710 |
Why?
| | Cost Sharing | 1 | 2020 | 14 | 0.700 |
Why?
| | Models, Economic | 2 | 2011 | 48 | 0.690 |
Why?
| | Information Dissemination | 1 | 2022 | 193 | 0.690 |
Why?
| | Chemotherapy, Adjuvant | 7 | 2023 | 334 | 0.670 |
Why?
| | Mammography | 3 | 2014 | 107 | 0.660 |
Why?
| | Preventive Health Services | 5 | 2023 | 134 | 0.650 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 25 | 0.640 |
Why?
| | Health Facilities | 1 | 2019 | 70 | 0.640 |
Why?
| | Spouses | 3 | 2017 | 84 | 0.640 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 287 | 0.610 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 296 | 0.610 |
Why?
| | Young Adult | 22 | 2022 | 10470 | 0.610 |
Why?
| | Survival Analysis | 10 | 2019 | 1219 | 0.600 |
Why?
| | Retirement | 4 | 2022 | 25 | 0.590 |
Why?
| | Reimbursement, Incentive | 1 | 2017 | 36 | 0.580 |
Why?
| | Job Satisfaction | 3 | 2013 | 170 | 0.560 |
Why?
| | Length of Stay | 6 | 2012 | 958 | 0.550 |
Why?
| | Healthy People Programs | 1 | 2016 | 8 | 0.550 |
Why?
| | Occupational Health Services | 2 | 2016 | 31 | 0.540 |
Why?
| | Bevacizumab | 1 | 2017 | 118 | 0.540 |
Why?
| | Logistic Models | 13 | 2023 | 1856 | 0.540 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2023 | 157 | 0.540 |
Why?
| | Chronic Pain | 1 | 2019 | 210 | 0.530 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 519 | 0.530 |
Why?
| | Outpatients | 1 | 2019 | 330 | 0.530 |
Why?
| | Job Description | 2 | 2013 | 10 | 0.530 |
Why?
| | Massachusetts | 4 | 2021 | 137 | 0.520 |
Why?
| | Rectal Neoplasms | 1 | 2016 | 122 | 0.500 |
Why?
| | Nursing Homes | 4 | 2013 | 136 | 0.500 |
Why?
| | Fee-for-Service Plans | 4 | 2023 | 79 | 0.480 |
Why?
| | State Government | 3 | 2014 | 41 | 0.480 |
Why?
| | Vaginal Smears | 1 | 2014 | 48 | 0.480 |
Why?
| | Longitudinal Studies | 10 | 2022 | 2416 | 0.470 |
Why?
| | Mouth Neoplasms | 3 | 2019 | 70 | 0.470 |
Why?
| | Health Personnel | 3 | 2022 | 581 | 0.450 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1361 | 0.450 |
Why?
| | Emergency Treatment | 1 | 2015 | 113 | 0.450 |
Why?
| | General Practice | 1 | 2014 | 27 | 0.450 |
Why?
| | Health Services Research | 4 | 2010 | 377 | 0.450 |
Why?
| | Sick Leave | 2 | 2019 | 12 | 0.440 |
Why?
| | Delivery of Health Care | 5 | 2024 | 844 | 0.440 |
Why?
| | Databases, Factual | 7 | 2021 | 1138 | 0.440 |
Why?
| | Behavioral Risk Factor Surveillance System | 4 | 2017 | 44 | 0.430 |
Why?
| | Sickness Impact Profile | 1 | 2013 | 50 | 0.430 |
Why?
| | Cost-Benefit Analysis | 8 | 2017 | 548 | 0.420 |
Why?
| | Insurance Claim Review | 2 | 2010 | 67 | 0.410 |
Why?
| | Survival Rate | 7 | 2020 | 1650 | 0.410 |
Why?
| | Homes for the Aged | 2 | 2013 | 19 | 0.410 |
Why?
| | Marital Status | 3 | 2007 | 41 | 0.410 |
Why?
| | Value of Life | 2 | 2008 | 19 | 0.410 |
Why?
| | Age Factors | 11 | 2022 | 2907 | 0.400 |
Why?
| | Work | 3 | 2010 | 17 | 0.400 |
Why?
| | Quality Improvement | 2 | 2018 | 958 | 0.400 |
Why?
| | Cross-Sectional Studies | 11 | 2023 | 4435 | 0.400 |
Why?
| | Neoplasm Metastasis | 3 | 2020 | 526 | 0.390 |
Why?
| | Risk Factors | 13 | 2021 | 8697 | 0.380 |
Why?
| | Periodicals as Topic | 2 | 2023 | 183 | 0.380 |
Why?
| | Health Services | 1 | 2012 | 104 | 0.370 |
Why?
| | Social Class | 4 | 2022 | 210 | 0.370 |
Why?
| | Surgical Procedures, Operative | 2 | 2012 | 210 | 0.370 |
Why?
| | Physician Self-Referral | 1 | 2010 | 1 | 0.360 |
Why?
| | Intestinal Perforation | 3 | 2016 | 38 | 0.360 |
Why?
| | Biomedical Research | 2 | 2020 | 588 | 0.360 |
Why?
| | Physicians | 1 | 2018 | 776 | 0.350 |
Why?
| | Waiting Lists | 1 | 2011 | 223 | 0.340 |
Why?
| | Recovery of Function | 1 | 2013 | 577 | 0.340 |
Why?
| | Financing, Personal | 2 | 2019 | 27 | 0.340 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2016 | 102 | 0.340 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 577 | 0.340 |
Why?
| | Astrocytoma | 1 | 2010 | 109 | 0.330 |
Why?
| | Radiation Oncology | 1 | 2010 | 76 | 0.330 |
Why?
| | Data Collection | 3 | 2014 | 636 | 0.330 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 200 | 0.330 |
Why?
| | Surveys and Questionnaires | 11 | 2018 | 4665 | 0.330 |
Why?
| | Administration, Oral | 2 | 2023 | 734 | 0.330 |
Why?
| | Propensity Score | 1 | 2010 | 225 | 0.320 |
Why?
| | Dentists | 1 | 2008 | 19 | 0.320 |
Why?
| | Life Expectancy | 1 | 2008 | 51 | 0.320 |
Why?
| | Persuasive Communication | 1 | 2008 | 13 | 0.320 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2018 | 39 | 0.310 |
Why?
| | Dental Care | 1 | 2008 | 28 | 0.310 |
Why?
| | HIV Infections | 2 | 2022 | 2473 | 0.310 |
Why?
| | Multivariate Analysis | 9 | 2019 | 1440 | 0.310 |
Why?
| | Odds Ratio | 9 | 2014 | 962 | 0.300 |
Why?
| | Communication | 2 | 2019 | 750 | 0.290 |
Why?
| | Pneumonectomy | 1 | 2008 | 126 | 0.290 |
Why?
| | Models, Econometric | 5 | 2017 | 34 | 0.290 |
Why?
| | Depression | 4 | 2021 | 1145 | 0.290 |
Why?
| | Patient Education as Topic | 1 | 2011 | 686 | 0.280 |
Why?
| | Time Factors | 11 | 2013 | 6165 | 0.270 |
Why?
| | Likelihood Functions | 5 | 2021 | 128 | 0.270 |
Why?
| | Confidence Intervals | 4 | 2013 | 309 | 0.270 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 376 | 0.270 |
Why?
| | Quality-Adjusted Life Years | 4 | 2017 | 103 | 0.260 |
Why?
| | Myocardial Infarction | 3 | 2023 | 931 | 0.260 |
Why?
| | Online Systems | 1 | 2005 | 24 | 0.260 |
Why?
| | Anxiety | 3 | 2021 | 853 | 0.250 |
Why?
| | Cohort Studies | 7 | 2023 | 4944 | 0.250 |
Why?
| | Cross Infection | 2 | 2017 | 202 | 0.250 |
Why?
| | Colonic Diseases | 2 | 2016 | 25 | 0.250 |
Why?
| | Referral and Consultation | 1 | 2010 | 646 | 0.250 |
Why?
| | Disability Evaluation | 1 | 2007 | 271 | 0.250 |
Why?
| | Cost Savings | 2 | 2018 | 75 | 0.250 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2014 | 2098 | 0.250 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2011 | 538 | 0.240 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 192 | 0.240 |
Why?
| | Health Services Needs and Demand | 3 | 2017 | 249 | 0.240 |
Why?
| | Needs Assessment | 2 | 2024 | 318 | 0.240 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 425 | 0.230 |
Why?
| | Models, Statistical | 4 | 2017 | 606 | 0.230 |
Why?
| | Substance-Related Disorders | 3 | 1997 | 950 | 0.230 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 465 | 0.230 |
Why?
| | Hospitals, Public | 1 | 2023 | 23 | 0.220 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 337 | 0.220 |
Why?
| | Colorado | 2 | 2023 | 4113 | 0.220 |
Why?
| | Forecasting | 5 | 2016 | 333 | 0.210 |
Why?
| | Intensive Care Units | 2 | 2017 | 622 | 0.210 |
Why?
| | Economics, Medical | 1 | 2022 | 4 | 0.210 |
Why?
| | Carcinoma | 2 | 2017 | 200 | 0.210 |
Why?
| | Risk Assessment | 6 | 2022 | 2987 | 0.210 |
Why?
| | Age Distribution | 4 | 2020 | 341 | 0.210 |
Why?
| | Hormones | 1 | 2023 | 132 | 0.210 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 783 | 0.210 |
Why?
| | Proportional Hazards Models | 5 | 2019 | 1087 | 0.210 |
Why?
| | Incidence | 5 | 2022 | 2335 | 0.210 |
Why?
| | Colonic Polyps | 2 | 2014 | 67 | 0.210 |
Why?
| | Health Behavior | 2 | 2019 | 707 | 0.200 |
Why?
| | Brain Neoplasms | 1 | 2010 | 980 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 863 | 0.200 |
Why?
| | Bisexuality | 1 | 2022 | 17 | 0.200 |
Why?
| | Food Supply | 1 | 2022 | 66 | 0.200 |
Why?
| | Treatment Outcome | 10 | 2019 | 9159 | 0.200 |
Why?
| | Hospital Charges | 3 | 2003 | 39 | 0.200 |
Why?
| | Smoking | 2 | 2019 | 1457 | 0.200 |
Why?
| | Hospitalization | 5 | 2016 | 1765 | 0.190 |
Why?
| | Decision Making | 2 | 2005 | 791 | 0.190 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 684 | 0.190 |
Why?
| | Internet | 1 | 2005 | 602 | 0.180 |
Why?
| | Retrospective Studies | 12 | 2021 | 12608 | 0.180 |
Why?
| | Sex Factors | 5 | 2022 | 1736 | 0.180 |
Why?
| | Homosexuality, Male | 1 | 2022 | 170 | 0.180 |
Why?
| | Feasibility Studies | 1 | 2023 | 741 | 0.180 |
Why?
| | Kentucky | 1 | 2020 | 35 | 0.180 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 71 | 0.180 |
Why?
| | Population Surveillance | 2 | 2022 | 395 | 0.180 |
Why?
| | California | 2 | 2018 | 367 | 0.180 |
Why?
| | Stress, Psychological | 2 | 2021 | 974 | 0.180 |
Why?
| | Benzodiazepines | 1 | 2021 | 115 | 0.170 |
Why?
| | Probability | 4 | 2023 | 294 | 0.170 |
Why?
| | Sample Size | 1 | 2000 | 115 | 0.170 |
Why?
| | Carrier State | 2 | 2017 | 55 | 0.170 |
Why?
| | Adolescent | 12 | 2020 | 17889 | 0.170 |
Why?
| | Exercise Therapy | 1 | 2023 | 351 | 0.170 |
Why?
| | Regression Analysis | 5 | 2021 | 959 | 0.170 |
Why?
| | Ownership | 2 | 2010 | 81 | 0.170 |
Why?
| | Diabetes Mellitus | 3 | 2018 | 906 | 0.170 |
Why?
| | Patient Selection | 3 | 2010 | 654 | 0.170 |
Why?
| | Infection Control | 2 | 2017 | 136 | 0.160 |
Why?
| | Activities of Daily Living | 2 | 2010 | 352 | 0.160 |
Why?
| | Language Development Disorders | 1 | 2019 | 38 | 0.160 |
Why?
| | Infant, Newborn | 4 | 2020 | 5077 | 0.160 |
Why?
| | Los Angeles | 2 | 2015 | 56 | 0.160 |
Why?
| | Anthracyclines | 3 | 2023 | 41 | 0.160 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2023 | 40 | 0.160 |
Why?
| | Cancer Pain | 1 | 2018 | 20 | 0.160 |
Why?
| | Taxoids | 3 | 2023 | 94 | 0.160 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2019 | 182 | 0.160 |
Why?
| | Carboplatin | 1 | 2018 | 139 | 0.150 |
Why?
| | Cetuximab | 1 | 2018 | 90 | 0.150 |
Why?
| | Hyperlipidemias | 1 | 2019 | 124 | 0.150 |
Why?
| | Ireland | 2 | 2016 | 25 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 373 | 0.150 |
Why?
| | Inpatients | 2 | 2012 | 380 | 0.150 |
Why?
| | Financing, Government | 1 | 2017 | 40 | 0.150 |
Why?
| | Unemployment | 2 | 2009 | 39 | 0.150 |
Why?
| | Patient Discharge | 1 | 2023 | 770 | 0.150 |
Why?
| | Managed Care Programs | 1 | 2018 | 135 | 0.140 |
Why?
| | Patient Protection and Affordable Care Act | 2 | 2015 | 100 | 0.140 |
Why?
| | Hypoglycemic Agents | 2 | 2018 | 1008 | 0.140 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 50 | 0.140 |
Why?
| | Cisplatin | 1 | 2018 | 263 | 0.140 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1127 | 0.140 |
Why?
| | Hospital Costs | 2 | 2011 | 105 | 0.140 |
Why?
| | Public Health Practice | 1 | 2017 | 63 | 0.140 |
Why?
| | Patient Rights | 2 | 2019 | 10 | 0.140 |
Why?
| | Heart Failure | 2 | 2023 | 1963 | 0.140 |
Why?
| | Language | 1 | 2019 | 258 | 0.140 |
Why?
| | Psychiatric Department, Hospital | 1 | 1996 | 15 | 0.140 |
Why?
| | Clinical Competence | 2 | 2014 | 912 | 0.140 |
Why?
| | Child Behavior | 1 | 1998 | 218 | 0.140 |
Why?
| | Sex Distribution | 3 | 2020 | 337 | 0.140 |
Why?
| | Drug Therapy | 1 | 2017 | 78 | 0.140 |
Why?
| | Lymph Nodes | 1 | 2019 | 423 | 0.130 |
Why?
| | Self Efficacy | 1 | 2019 | 361 | 0.130 |
Why?
| | Child, Preschool | 4 | 2020 | 9133 | 0.130 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2016 | 48 | 0.130 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 1996 | 14 | 0.130 |
Why?
| | Residence Characteristics | 2 | 2008 | 276 | 0.130 |
Why?
| | Smoking Cessation | 1 | 2019 | 377 | 0.130 |
Why?
| | Patient Admission | 1 | 1997 | 175 | 0.130 |
Why?
| | Follow-Up Studies | 6 | 2019 | 4440 | 0.120 |
Why?
| | Minority Groups | 1 | 2017 | 230 | 0.120 |
Why?
| | Child Development | 1 | 2019 | 389 | 0.120 |
Why?
| | Colorectal Surgery | 1 | 2015 | 22 | 0.120 |
Why?
| | Infant | 3 | 2020 | 7979 | 0.120 |
Why?
| | Metformin | 1 | 2018 | 278 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 139 | 0.120 |
Why?
| | Autism Spectrum Disorder | 1 | 2019 | 322 | 0.120 |
Why?
| | Mastectomy, Segmental | 3 | 2009 | 76 | 0.120 |
Why?
| | Research Design | 3 | 2007 | 946 | 0.120 |
Why?
| | National Health Programs | 1 | 2014 | 20 | 0.120 |
Why?
| | Pilot Projects | 3 | 2021 | 1377 | 0.120 |
Why?
| | Computer Simulation | 2 | 2023 | 881 | 0.110 |
Why?
| | Systems Integration | 1 | 2013 | 38 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1996 | 179 | 0.110 |
Why?
| | Cerebrovascular Disorders | 1 | 2014 | 82 | 0.110 |
Why?
| | Exercise | 2 | 2023 | 1609 | 0.110 |
Why?
| | Prospective Studies | 3 | 2017 | 6264 | 0.110 |
Why?
| | Health Status Indicators | 1 | 2014 | 155 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 3 | 2021 | 815 | 0.110 |
Why?
| | Quality of Health Care | 2 | 2008 | 576 | 0.110 |
Why?
| | Helping Behavior | 1 | 2013 | 15 | 0.110 |
Why?
| | Child | 6 | 2020 | 18488 | 0.110 |
Why?
| | Occupations | 1 | 2012 | 36 | 0.100 |
Why?
| | Medical Audit | 1 | 2013 | 75 | 0.100 |
Why?
| | Maryland | 3 | 1997 | 37 | 0.100 |
Why?
| | Mandatory Programs | 1 | 2012 | 16 | 0.100 |
Why?
| | Pregnancy, Unwanted | 1 | 2012 | 13 | 0.100 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2012 | 23 | 0.100 |
Why?
| | Life Tables | 2 | 2008 | 17 | 0.100 |
Why?
| | Cause of Death | 1 | 2014 | 368 | 0.100 |
Why?
| | Attitude to Health | 2 | 2019 | 409 | 0.100 |
Why?
| | Cost Control | 1 | 2012 | 40 | 0.100 |
Why?
| | Goals | 2 | 2023 | 158 | 0.100 |
Why?
| | Mental Disorders | 2 | 1997 | 902 | 0.100 |
Why?
| | Community Health Services | 1 | 2013 | 212 | 0.100 |
Why?
| | Self Disclosure | 1 | 2011 | 59 | 0.100 |
Why?
| | Contraception Behavior | 1 | 2012 | 80 | 0.100 |
Why?
| | Sepsis | 1 | 2017 | 515 | 0.100 |
Why?
| | Educational Status | 1 | 2013 | 413 | 0.100 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 65 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 1996 | 430 | 0.100 |
Why?
| | Retreatment | 1 | 2011 | 70 | 0.090 |
Why?
| | Mastectomy | 1 | 2011 | 99 | 0.090 |
Why?
| | Video Recording | 1 | 2011 | 147 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2010 | 2800 | 0.090 |
Why?
| | Economics, Nursing | 1 | 2010 | 1 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2014 | 497 | 0.090 |
Why?
| | Stress, Physiological | 1 | 2013 | 399 | 0.090 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 55 | 0.090 |
Why?
| | Access to Information | 1 | 2010 | 50 | 0.090 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 239 | 0.090 |
Why?
| | Consumer Behavior | 1 | 1990 | 66 | 0.090 |
Why?
| | Sentinel Surveillance | 1 | 2009 | 38 | 0.090 |
Why?
| | Standard of Care | 1 | 2010 | 63 | 0.090 |
Why?
| | Sex Characteristics | 2 | 2022 | 641 | 0.090 |
Why?
| | Occult Blood | 1 | 2009 | 27 | 0.080 |
Why?
| | Comparative Effectiveness Research | 1 | 2010 | 130 | 0.080 |
Why?
| | Insurance Claim Reporting | 1 | 2009 | 22 | 0.080 |
Why?
| | Women's Health | 2 | 2012 | 271 | 0.080 |
Why?
| | Ohio | 1 | 2009 | 136 | 0.080 |
Why?
| | Private Sector | 1 | 2009 | 51 | 0.080 |
Why?
| | Psychometrics | 1 | 2013 | 615 | 0.080 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2009 | 59 | 0.080 |
Why?
| | Bias | 1 | 2010 | 179 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2013 | 519 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 776 | 0.080 |
Why?
| | Physical Exertion | 1 | 2010 | 206 | 0.080 |
Why?
| | Patient Satisfaction | 1 | 2013 | 585 | 0.080 |
Why?
| | Home Nursing | 1 | 2008 | 27 | 0.080 |
Why?
| | Reimbursement Mechanisms | 1 | 2009 | 78 | 0.080 |
Why?
| | Education, Professional | 1 | 2008 | 19 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 324 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2010 | 538 | 0.080 |
Why?
| | Radiotherapy | 1 | 2008 | 177 | 0.070 |
Why?
| | Pain | 2 | 2010 | 712 | 0.070 |
Why?
| | Self Care | 1 | 2010 | 354 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 499 | 0.070 |
Why?
| | Leukemia | 1 | 2008 | 209 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2010 | 475 | 0.070 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2006 | 107 | 0.070 |
Why?
| | Lung Diseases | 1 | 2012 | 710 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 1098 | 0.070 |
Why?
| | Charities | 1 | 2005 | 9 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2019 | 3022 | 0.060 |
Why?
| | Empirical Research | 1 | 2005 | 22 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1216 | 0.060 |
Why?
| | Hospice Care | 1 | 2007 | 186 | 0.060 |
Why?
| | Diagnosis-Related Groups | 1 | 2003 | 27 | 0.060 |
Why?
| | Pennsylvania | 1 | 2023 | 94 | 0.060 |
Why?
| | Prevalence | 1 | 2010 | 2264 | 0.060 |
Why?
| | Pandemics | 2 | 2022 | 1334 | 0.060 |
Why?
| | Resource Allocation | 1 | 2003 | 38 | 0.060 |
Why?
| | Florida | 2 | 2014 | 73 | 0.060 |
Why?
| | Health Surveys | 2 | 2007 | 446 | 0.050 |
Why?
| | Causality | 1 | 2023 | 106 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2005 | 596 | 0.050 |
Why?
| | Women, Working | 1 | 2002 | 9 | 0.050 |
Why?
| | Markov Chains | 2 | 2017 | 114 | 0.050 |
Why?
| | Selection Bias | 1 | 2002 | 33 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 633 | 0.050 |
Why?
| | Sampling Studies | 1 | 2002 | 95 | 0.050 |
Why?
| | Mastectomy, Radical | 1 | 2001 | 2 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 722 | 0.050 |
Why?
| | Palliative Care | 1 | 2007 | 642 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 279 | 0.050 |
Why?
| | Family Characteristics | 1 | 2002 | 153 | 0.050 |
Why?
| | Normal Distribution | 1 | 2000 | 19 | 0.040 |
Why?
| | Drug Evaluation | 1 | 2000 | 79 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 2001 | 95 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2578 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 941 | 0.040 |
Why?
| | Nursing Research | 1 | 2000 | 40 | 0.040 |
Why?
| | Presenteeism | 1 | 2019 | 5 | 0.040 |
Why?
| | Etidronic Acid | 1 | 1998 | 3 | 0.040 |
Why?
| | Alendronate | 1 | 1998 | 8 | 0.040 |
Why?
| | Informed Consent | 1 | 2000 | 161 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 26 | 0.040 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 1998 | 36 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 372 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2019 | 141 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 276 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 13 | 0.040 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 116 | 0.040 |
Why?
| | Ecosystem | 1 | 2022 | 526 | 0.040 |
Why?
| | Smoking Prevention | 1 | 1998 | 156 | 0.040 |
Why?
| | Alzheimer Disease | 1 | 2002 | 438 | 0.040 |
Why?
| | Tennessee | 1 | 2017 | 42 | 0.040 |
Why?
| | Spinal Fractures | 1 | 1998 | 78 | 0.040 |
Why?
| | Puberty | 1 | 1998 | 137 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2018 | 187 | 0.040 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 1997 | 35 | 0.040 |
Why?
| | Patient Isolation | 1 | 2017 | 16 | 0.040 |
Why?
| | Catheter-Related Infections | 1 | 2017 | 61 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2017 | 183 | 0.040 |
Why?
| | Utilization Review | 1 | 1996 | 34 | 0.030 |
Why?
| | Patient Dropouts | 1 | 1997 | 65 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 65 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 47 | 0.030 |
Why?
| | Schools | 1 | 2000 | 400 | 0.030 |
Why?
| | Arizona | 1 | 1996 | 67 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2018 | 154 | 0.030 |
Why?
| | Health Policy | 1 | 2019 | 334 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 724 | 0.030 |
Why?
| | Anticholesteremic Agents | 1 | 2018 | 129 | 0.030 |
Why?
| | Hospitals, Community | 1 | 1996 | 47 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 1996 | 33 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 445 | 0.030 |
Why?
| | Health Resources | 2 | 2009 | 122 | 0.030 |
Why?
| | Telemedicine | 1 | 2023 | 667 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 432 | 0.030 |
Why?
| | Protoporphyrins | 1 | 1993 | 17 | 0.030 |
Why?
| | Acute Disease | 1 | 1996 | 914 | 0.030 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 422 | 0.030 |
Why?
| | Lead | 1 | 1993 | 43 | 0.030 |
Why?
| | Learning Curve | 1 | 2014 | 63 | 0.030 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1718 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1642 | 0.030 |
Why?
| | Calcium | 1 | 1998 | 1103 | 0.030 |
Why?
| | Societies, Medical | 1 | 2016 | 684 | 0.030 |
Why?
| | Community Participation | 1 | 2013 | 118 | 0.030 |
Why?
| | General Surgery | 1 | 2014 | 129 | 0.030 |
Why?
| | Pregnancy | 2 | 2012 | 5548 | 0.030 |
Why?
| | Stroke | 1 | 2020 | 1016 | 0.030 |
Why?
| | Risk | 1 | 2014 | 819 | 0.020 |
Why?
| | Gastroenterology | 1 | 2014 | 158 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 390 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 3339 | 0.020 |
Why?
| | Contraception | 1 | 2012 | 118 | 0.020 |
Why?
| | Hepatitis B | 1 | 1991 | 53 | 0.020 |
Why?
| | Work Capacity Evaluation | 1 | 2010 | 11 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 302 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1064 | 0.020 |
Why?
| | Budgets | 1 | 2009 | 14 | 0.020 |
Why?
| | Sigmoidoscopy | 1 | 2009 | 10 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2010 | 160 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2013 | 478 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 161 | 0.020 |
Why?
| | Prostatectomy | 1 | 2009 | 98 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1991 | 262 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 450 | 0.020 |
Why?
| | Psychology | 1 | 2008 | 83 | 0.020 |
Why?
| | Demography | 1 | 2008 | 261 | 0.020 |
Why?
| | Mortality | 1 | 2008 | 290 | 0.020 |
Why?
| | Lifting | 1 | 2006 | 4 | 0.020 |
Why?
| | Least-Squares Analysis | 1 | 2006 | 73 | 0.020 |
Why?
| | Illinois | 1 | 2006 | 37 | 0.020 |
Why?
| | Telephone | 1 | 2007 | 153 | 0.020 |
Why?
| | Body Weight | 1 | 1990 | 867 | 0.020 |
Why?
| | Patient Compliance | 1 | 2009 | 524 | 0.020 |
Why?
| | Prejudice | 1 | 2006 | 56 | 0.020 |
Why?
| | Burnout, Professional | 1 | 2010 | 322 | 0.020 |
Why?
| | Myocardial Revascularization | 1 | 2003 | 67 | 0.010 |
Why?
| | Vaccination | 1 | 1991 | 1209 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 390 | 0.010 |
Why?
| | Behavior | 1 | 2002 | 91 | 0.010 |
Why?
| | Episode of Care | 1 | 2001 | 6 | 0.010 |
Why?
| | Decision Trees | 1 | 2001 | 81 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2002 | 241 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 536 | 0.010 |
Why?
| | Reoperation | 1 | 2001 | 525 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2002 | 919 | 0.010 |
Why?
| | Estrogens | 1 | 1998 | 315 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 1998 | 962 | 0.010 |
Why?
| | Estradiol | 1 | 1998 | 452 | 0.010 |
Why?
| | Lead Poisoning | 1 | 1993 | 17 | 0.010 |
Why?
| | ROC Curve | 1 | 1993 | 451 | 0.010 |
Why?
| | Reference Values | 1 | 1993 | 744 | 0.010 |
Why?
| | Program Evaluation | 1 | 1991 | 836 | 0.000 |
Why?
|
|
Bradley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|